Company intelligence / Profile preview
Integrated Nanotherapeutics
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
Integrated Nanotherapeutics has developed a proprietary LNP-based platform capable of delivering multiple therapeutic modalities—including mRNA and small molecule immunomodulators—to induce antigen-specific immune tolerance. Their lead program targets type 1 diabetes and is currently in preclinical development with support from Breakthrough T1D. The company’s founding team has contributed to the development of five approved LNP drugs.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesBiologics (including mRNA, siRNA, peptides)Lipid nanoparticles (LNPs) as delivery vehicles
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Integrated Nanotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Integrated Nanotherapeutics.